Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

As an approach to treatment of advanced prostate cancer, a medicinal chemistry program derived from a novel androgen receptor ligand 8a led to androgen receptor downregulator (10b), for which high plasma levels following oral administration in a preclinical model compensate for moderate cellular potency.